drugset / Trial / NCT01102660

Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

NCT01102660

Phase 2 Completed 172 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

PH-797804 is a potent inhibitor of inflammatory mediators that have a potential role in pain signalling following nerve injury and inflammation. Blocking such mediators may potentially have a therapeutic benefit by reducing pain.

Timeline

Start
2010-05
Primary completion
2011-02
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 500 mg
Subject PH-797804 Small molecule 6 mg

Indications